CYBIN INC. CEO Michael Halstead will participate in a virtual fireside chat at the TD Cowen neuropsychiatry summit on September 23, 2026. Investors will be able to watch the webcast live, with a replay available through Helus Pharma’s Events & Presentations page after the session.

Key Highlights

  • Michael Halstead will participate in the virtual summit session on September 23, 2026.
  • The webcast will be available live, with a replay posted to the company’s Events & Presentations page.
  • HLP003 is in Phase 3 development, while HLP004 is in Phase 2 development.

CYBIN INC. (NASDAQ: HELP) is a major pharmaceuticals company. Its commercial operating name, Helus Pharma, will have Chief Executive Officer Michael Halstead participate in a virtual fireside chat at the TD Cowen Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026.

CEO Appearance and Company Programs

The discussion will be webcast live, and a replay will remain available on Helus Pharma’s Events & Presentations page. CYBIN develops novel serotonergic agonists, which it describes as proprietary compounds designed to activate serotonin pathways. Its stated focus includes mental health conditions such as depression and anxiety. The company is developing HLP003 for adjunctive treatment of major depressive disorder and HLP004 for generalized anxiety disorder. CYBIN also says it maintains a wider research portfolio of investigational novel serotonergic agonists. The release contains forward-looking statements about the planned summit appearance and efforts involving drug discovery platforms, delivery systems, formulations and treatment regimens. The filing identifies potential risks including securities-market fluctuations, macroeconomic conditions, regulatory restrictions, disease outbreaks and the company’s ability to achieve its Business objectives.